mProX™ Human SIGLEC10 Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

SIGLEC10, a sialic acid-binding immunoglobulin-like lectin, has various applications in cancer immunotherapy and solid tumor treatment. In one study, a humanized monoclonal antibody called IMM47 was developed to target CD24 and block its interaction with SIGLEC10. IMM47 demonstrated exceptional anti-tumor efficacy and can be used as a monotherapy or in combination with other antibodies for cancer immunotherapy. Another study utilized attenuated Salmonella carrying siRNA-CD24 to improve the effectiveness of the chemotherapy drug oxaliplatin in hepatocellular carcinoma (HCC) treatment. CD24, which interacts with SIGLEC10 on tumor-associated macrophages, was targeted to enhance the efficacy of oxaliplatin. Additionally, SIGLEC10 was found to be enriched in infiltrating myeloid cells within gastroenteropancreatic neuroendocrine tumors (GEP-NETs), suggesting its potential as an immune checkpoint target for precision medicine therapeutics. Furthermore, targeted glycan degradation combined with cellular immunotherapy, such as chimeric antigen receptor T (CAR-T) cell therapy, showed promising results in enhancing the treatment of solid tumors. Desialylation of cancer cells and blockade of the SIGLEC10 checkpoint on macrophages improved the therapeutic effect of CAR-T cells. Lastly, the interactions of B cell SIGLECs, including SIGLEC10, with sialylated self-antigens and other ligands were found to be involved in the prevention of autoimmunity and the quality control of signaling-competent B cells. These findings highlight the diverse applications and potential of SIGLEC10 in cancer immunotherapy and solid tumor treatment.